Raytheon Technologies Corp vs 10X Genomics Inc — how do they compare? Raytheon Technologies Corp trades at $223.51 (market cap $302.06B), while 10X Genomics Inc trades at $58.47 (market cap $7.64B). The key difference: Raytheon Technologies Corp is far larger — about 39.5× 10X Genomics Inc's market cap, and Raytheon Technologies Corp pays a 1.3% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| RTX | TXG | |
|---|---|---|
Market Cap | $302.06B | $7.64B |
Sector | Industrials | Health |
52-Week High | $224.12 | $58.57 |
52-Week Low | $151.75 | $11.34 |
Enterprise Value | $332.61B | $7.17B |
Dividend Yield | 1.3% | — |
Signals from Pluang's Aura AI — not financial advice
RTX trades at $223.03, down 0.1% on the day, with a bullish technical outlook supported by moving averages and a recent $515 million Navy radar contract. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue grew to $88.6 billion in 2025, and net income margin improved to 8.28%. The stock is near its consensus price target of $233.14, with no analyst sell ratings.
The outlook for RTX is positive, driven by defense contract wins and expanding profit margins, but risks include high valuation multiples and geopolitical uncertainties. Earnings growth and execution on backlog are key catalysts for further upside, though the stock's elevated P/E ratio of 39.27 warrants caution amid potential market volatility.
TXG is trading at $52.03, up 14.1% in the past 24 hours, reflecting strong momentum. The stock exhibits a bullish technical signal with moving averages supporting upward trends, while RSI levels suggest mild overbought conditions. Fundamentally, the company reported Q2 2026 revenue of $151 million, beating estimates, and has shown consistent earnings beats in recent quarters. Recent news highlights collaborations with Cleveland Clinic and the acquisition of Proteintech Genomics, expanding its multiomics capabilities and reinforcing growth prospects.
The outlook for TXG is cautiously optimistic, driven by earnings outperformance and strategic expansions, but risks include persistent net losses and high valuation multiples. Analyst consensus is mixed with a $46 price target, indicating potential downside from current levels. Investors should weigh revenue growth against profitability challenges and monitor execution on new initiatives for sustained upside.
Trailing returns across standard periods
Latest headlines on both assets
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →